Market Research Report
Transcatheter Aortic Valve Implantation Market | Europe | Units Sold, Average Selling Prices, Forecasts | 2018-2024| MedCore
|Published by||iData Research Inc.||Product code||718249|
|Published||Content info||344 Pages
Delivery time: 1-2 business days
|Transcatheter Aortic Valve Implantation Market | Europe | Units Sold, Average Selling Prices, Forecasts | 2018-2024| MedCore|
|Published: August 1, 2018||Content info: 344 Pages||
The primary method for treating aortic heart valve conditions is through the use of open surgery to place a replacement valve. Biological tissue valves can be allografts (donated by other people after they die), xenografts (porcine valves) or autografts (using the patient's own pulmonary valve, which in turn, need to be replaced).
TAVI in Europe is approved for the treatment of severe aortic stenosis for symptomatic patients at intermediate, high or extreme risk for open heart surgery. Low-risk patients represent the next frontier in the TAVI market. Expansion into the low-risk population may prove to be more challenging than the higher-risk populations, which could cause TAVI sales to moderate over the forecast period.